m6A 甲基化修饰非编码RNA 调控病理性心脏重塑的作用.

BACKGROUND: N6-methyladenosine (m6A) is a hot research topic in the mechanism of pathological cardiac remodeling and plays an important role in the development of cardiovascular diseases. OBJECTIVE: To summarize the possible mechanism by which m6A modification in non-coding RNAs regulates the main processes of pathological cardiac remodeling, such as pathological cardiac hypertrophy, cardiomyocyte death, myocardial fibrosis and vascular remodeling. METHODS: “m6A, non-coding RNA, pathological cardiac hypertrophy, cardiomyocyte apoptosis, cardiomyocyte pyroptosis, cardiomyocyte ferroptosis, myocardial fibrosis, vascular remodeling” were used as search terms in Chinese and English. Relevant literature from CNKI, PubMed and Web of Science databases published from January 1974 to April 2023 was retrieved, and finally 86 eligible articles were reviewed. RESULTS AND CONCLUSION: m6A modification is a highly dynamic and reversible modification. Pathological cardiac remodeling mainly involves pathological cardiac hypertrophy, cardiomyocyte apoptosis, cardiomyocyte pyroptosis, cardiomyocyte ferroptosis, myocardial fibrosis and vascular remodeling. m6A-related enzymes can regulate pathological cardiac remodeling processes through various non-coding RNAs and different signaling pathways, which can be used as a new potential intervention for cardiovascular diseases. In pathological cardiac remodeling, research on the regulatory relationship between m6A modification and non-coding RNAs is still in its infancy. With the development of epigenetics, m6A modification in non-coding RNAs is expected to have a new development in the regulation of pathological cardiac remodeling. [ABSTRACT FROM AUTHOR]